Swedish Orphan Biovitrum (Buy, TP: SEK330.00) - Likely to beat its guidance
We expect EBITA of SEK3,521m for 2018, which is slightly above the top end of Sobi’s full-year guidance range. We anticipate patient acquisition in haemophilia will continue to grow strongly in 2019; and there should be a tailwind on revenues in the final quarter driven by a seasonal effect from patients switched in Q3 and Q4. A key aspect of the Q4 report will be the outlook for 2019. We expect Sobi to give cautious guidance, as it always does. We reiterate our BUY and target price of SEK330.Swedish Orphan Biovitrum AB is a healthcare company focused on rare diseases. Co. develops, manufactures and commercializes treatments with a particular focus on four therapeutic areas: Inflammation, Genetics & Metabolism, Haemophilia and Neonatology. Co. also markets a portfolio of rare disease products for partner companies. Co.'s pipeline programmes include research and development focused on recombinant protein drugs in late preclinical and clinical phase for indications.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.